Atrial Fibrillation as a Possible Adverse Reaction to Evolocumab

Area of Science:

• Cardiovascular Medicine
• Pharmacology

Background:

• Evolocumab is an FDA-approved proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i).
• PCSK9 inhibitors are indicated for patients with established atherosclerotic cardiovascular disease (ASCVD).
• These agents significantly reduce the risk of myocardial infarction, stroke, and coronary revascularization.

Observation:

• This report details an extremely rare potential adverse event associated with evolocumab use.
• The observed side effect was atrial fibrillation (AF).

Findings:

• Atrial fibrillation (AF) is identified as a potential, albeit extremely rare, side effect of evolocumab.
• This finding contributes to the known safety profile of PCSK9 inhibitors.

Implications:

• Increased physician awareness of this rare side effect is crucial for patient safety.
• Further monitoring and research may be warranted to fully understand the association between evolocumab and atrial fibrillation.